NP38619 Compounded Aseptic Medicines

Concepts

• edinburgh
• pharmaceutical products
• aseptic medicines
• aseptic
• medicines
• compounded
• nhs scotland
• scotland
• regulation 72(1)(c
• unnecessary disruption

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Description

This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. The Goods have been separated into four (4) categories, each of which is identified as a “Lot”. Lot 1 - Atezolizumab, Cetuximab, Doxorubicin, Epirubicin, Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab, Pembrolizumab & Pertuzumab Lot 2 - Cyclophosphamide, Fluorouracil, Irinotecan, Methotrexate & Rituximab (Mabthera®), (Rixathon®), (Truxima®) Lot 3 - Bortezomib, Carboplatin, Cisplatin, Docetaxel, Gemcitabine, Oxaliplatin, Vincristine & Trastuzumab (Herceptin®), (Herzuma®) Lot 4 - The molecules included in this Lot are, Bevacizumab, Cytarabine, Infliximab (Zessly®), Insulin, Methotrexate, Natalizumab, Nivolumab, Paclitaxel, Pemetrexed, Tocilizumab, Trastuzumab (Kanjinti®), (Ontruzant®), Trastuzumab Subcutaneous & Vedolizumab The Framework Participant was required to supply Goods to designated delivery points throughout Scotland for use by Participating Authorities.

Ammendments to Previous Notice

Award Detail

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Contract modified due to unforeseen circumstances.

Legal Justification

This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector to maintain necessary supply due to circumstances unforeseen by the Authority, and at this time have rendered this modification necessary, in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.

Other Information

The estimated value of the Framework Agreement referred to in Section V11.1.6 cover(s) the 48 month contract duration of the Framework Agreement. The estimated value in Section V.2.4 covers the additional 12 month extension period of the Framework Agreement. (SC Ref:761417)